Related references
Note: Only part of the references are listed.Previous corticosteroid exposure associates with an increased Pneumocystis jirovecii pneumonia mortality among HIV-negative patients: a global research network with a follow-up multicenter case-control study
Lilian Vargas Barahona et al.
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2023)
Efficacy and safety of Isavuconazole for the treatment of invasive Aspergillus infection-an update of the literature
Geetha Sivasubramanian et al.
EXPERT OPINION ON PHARMACOTHERAPY (2022)
Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study
Michele Bartoletti et al.
CLINICAL INFECTIOUS DISEASES (2021)
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
Johan A Maertens et al.
LANCET (2021)
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
Amit V. Desai et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
Thomas F. Patterson et al.
CLINICAL INFECTIOUS DISEASES (2016)
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
Johan A. Maertens et al.
LANCET (2016)
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: Impact of other therapies on outcome
TF Patterson et al.
CLINICAL INFECTIOUS DISEASES (2005)
Share Paper
